Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -11.20% is in line with its 5-year average of -10.87%, near the low end of its 5-year range (-29.86%–35.28%).
As of the fiscal period ended Tuesday, June 30, 2026. 23.84% above its 12-month average of -14.70%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -11.20%.
RETURN ON EQUITY (ROE)
-11.20%
RETURN ON EQUITY (ROE) AVG TTM
-14.70%
RETURN ON EQUITY (ROE) AVG 3Y
-11.32%
RETURN ON EQUITY (ROE) AVG 5Y
-10.87%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+23.84%
CURRENT VS 3Y AVG
+1.07%
CURRENT VS 5Y AVG
-3.03%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-38.55%
median of 489 covered companies
CURRENT VS SECTOR MEDIAN
+70.95%
vs the sector median at left
AirSculpt Technologies, Inc.
Market Cap
$141.09M
Return on Equity (ROE)
-11.20%
TTM Avg
-14.70%
3Y Avg
-11.32%
5Y Avg
-10.87%
Market Cap
$141.70M
Return on Equity (ROE)
68.12%
TTM Avg
-94.32%
3Y Avg
-166.28%
5Y Avg
-128.51%
Market Cap
$139.63M
Return on Equity (ROE)
-44.26%
TTM Avg
-34.18%
3Y Avg
285.39%
5Y Avg
-5868.11%
Market Cap
$145.39M
Return on Equity (ROE)
-30.03%
TTM Avg
-86.56%
3Y Avg
-69.53%
5Y Avg
-37.30%
Market Cap
$146.95M
Return on Equity (ROE)
-131.85%
TTM Avg
-36.69%
3Y Avg
-135.43%
5Y Avg
-129.92%
Market Cap
$137.57M
Return on Equity (ROE)
-10.08%
TTM Avg
-25.77%
3Y Avg
-36.68%
5Y Avg
-27.09%
Market Cap
$135.17M
Return on Equity (ROE)
-266.86%
TTM Avg
156.76%
3Y Avg
98.17%
5Y Avg
-694.29%
Market Cap
$148.07M
Return on Equity (ROE)
-183.44%
TTM Avg
-114.28%
3Y Avg
-67.72%
5Y Avg
-46.03%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| AirSculpt Technologies, Inc. (AIRS) | $141.09M | -11.20% | -14.70% | -11.32% | -10.87% |
| Fortress Biotech, Inc. (FBIOP)vs › | $141.70M | 68.12% | -94.32% | -166.28% | -128.51% |
| Alpha Cognition Inc (ACOG)vs › | $139.63M | -44.26% | -34.18% | 285.39% | -5868.11% |
| Freenome, Inc. (FRNM)vs › | $138.31M | N/A | N/A | N/A | N/A |
| Immuneering Corporation (IMRX)vs › | $145.39M | -30.03% | -86.56% | -69.53% | -37.30% |
| Korsana Biosciences, Inc. (KRSA)vs › | $146.95M | -131.85% | -36.69% | -135.43% | -129.92% |
| KORU Medical Systems, Inc. (KRMD)vs › | $137.57M | -10.08% | -25.77% | -36.68% | -27.09% |
| LifeMD, Inc. (LFMD)vs › | $135.17M | -266.86% | 156.76% | 98.17% | -694.29% |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $148.07M | -183.44% | -114.28% | -67.72% | -46.03% |
| Health Catalyst, Inc. (HCAT)vs › | $131.16M | -262.64% | -45.72% | -38.99% | -37.83% |
ROE
-11.2%
ROA
-6.1%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -11.20% |
| 2026-03-31 | -11.19% |
| 2025-12-31 | -13.30% |
| 2025-09-30 | -21.90% |
| 2025-06-30 | -15.92% |
| 2025-03-31 | -22.15% |
| 2024-12-31 | -10.41% |
| 2024-09-30 | -9.44% |
| 2024-06-30 | -4.02% |
| 2024-03-31 | 1.87% |
| 2023-12-31 | -5.33% |
| 2023-09-30 | -8.43% |
| 2023-06-30 | -15.72% |
| 2023-03-31 | -18.61% |
| 2022-12-31 | -20.74% |
| 2022-09-30 | -29.86% |
| 2022-06-30 | -6.37% |
| 2022-03-31 | 3.60% |
| 2021-12-31 | 12.63% |
| 2021-09-30 | 35.28% |
| 2021-06-30 | 30.38% |
| 2020-12-31 | 4.65% |
